Are you a patient looking to learn more about aiSLE™ DX?
Read the article on LupusCorner to learn more about the test and it's development
Request an aiSLE™ DX Flare Risk Index Welcome Kit to start using the test with your clinician. Request a Welcome Kit
Now Available
aiSLE™ DX Flare Risk Index is the first proactive test for lupus (SLE). Identify the risk of a patient experiencing a flare in the next 12 weeks.
Indication
Systemic Lupus Erythematosus (SLE)
Sample Source
Blood
Result
- Risk score derived from artificial intelligence algorithm
- Immunologic measures of eleven cytokines
Explore the validation and development efforts
Test Accuracy
The Odds Ratio (OR) calculated for pre-flare vs pre-nonflare patients with positive vs. negative score approaches 5.0 and is highly significant (p= 0.0015). This OR indicates that a patient with a positive aiSLE DX Flare Risk Index score is almost 5 times more likely to flare than a patient with a negative score.
Test Development
aiSLE™ DX Flare Risk Index was developed through clinical studies conducted at several National Institutes of Health-designated Autoimmunity Centers of Excellence in the United States. Participants in the clinical studies contributed blood samples and had their lupus flare status assessed by a rheumatologist using the SLEDAI, the gold standard for assessing a lupus patient’s current disease activity.
People of diverse racial and ethnic backgrounds participated in the studies including European Americans, African Americans, and Native Americans.
About the Progentec Laboratory
The Progentec laboratory is both CLIA-certified & CAP-accredited. It is based in Oklahoma City at the Oklahoma Medical Research Foundation. Our lab team has over 50 years of lab operations experience and can provide insight into best practices regarding cost-effective, accurate testing.